Moleculin Biotech Statistics
Share Statistics
Moleculin Biotech has 3.00M shares outstanding. The number of shares has increased by -91.49% in one year.
| Shares Outstanding | 3.00M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 23.06% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 2.90M |
| Failed to Deliver (FTD) Shares | 55 |
| FTD / Avg. Volume | 0.12% |
Short Selling Information
The latest short interest is 122.38K, so 4.08% of the outstanding shares have been sold short.
| Short Interest | 122.38K |
| Short % of Shares Out | 4.08% |
| Short % of Float | 4.23% |
| Short Ratio (days to cover) | 5.63 |
Valuation Ratios
The PE ratio is -0.85 and the forward PE ratio is -0.45.
| PE Ratio | -0.85 |
| Forward PE | -0.45 |
| PS Ratio | 0 |
| Forward PS | 0.2 |
| PB Ratio | 0.98 |
| P/FCF Ratio | -1.05 |
| PEG Ratio | n/a |
Enterprise Valuation
Moleculin Biotech Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 3.86, with a Debt / Equity ratio of 0.
| Current Ratio | 3.86 |
| Quick Ratio | 3.86 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.14% and return on capital (ROIC) is -111.2%.
| Return on Equity (ROE) | -1.14% |
| Return on Assets (ROA) | -0.78% |
| Return on Capital (ROIC) | -111.2% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -1.65M |
| Employee Count | 18 |
| Asset Turnover | 0 |
| Inventory Turnover | 127.00K |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -73.1% in the last 52 weeks. The beta is 1.86, so Moleculin Biotech 's price volatility has been higher than the market average.
| Beta | 1.86 |
| 52-Week Price Change | -73.1% |
| 50-Day Moving Average | 2.55 |
| 200-Day Moving Average | 3.84 |
| Relative Strength Index (RSI) | 43.05 |
| Average Volume (20 Days) | 47.55K |
Income Statement
In the last 12 months, Moleculin Biotech had revenue of $0 and earned -$29.77M in profits. Earnings per share was $-15.07.
| Revenue | 0 |
| Gross Profit | -127.00K |
| Operating Income | -29.63M |
| Net Income | -29.77M |
| EBITDA | -29.50M |
| EBIT | - |
| Earnings Per Share (EPS) | -15.07 |
Balance Sheet
The company has $23.55M in cash and $574.00K in debt, giving a net cash position of $22.98M.
| Cash & Cash Equivalents | 23.55M |
| Total Debt | 574.00K |
| Net Cash | 22.98M |
| Retained Earnings | -131.60M |
| Total Assets | 23.39M |
| Working Capital | 6.01M |
Cash Flow
In the last 12 months, operating cash flow was -$24.10M and capital expenditures -$124.00K, giving a free cash flow of -$24.23M.
| Operating Cash Flow | -24.10M |
| Capital Expenditures | -124.00K |
| Free Cash Flow | -24.23M |
| FCF Per Share | -12.26 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
MBRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -644.02% |
| FCF Yield | -344.87% |
Analyst Forecast
The average price target for MBRX is $24, which is 925.6% higher than the current price. The consensus rating is "Buy".
| Price Target | $24 |
| Price Target Difference | 925.6% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
Stock Splits
The last stock split was on Mar 22, 2024. It was a backward split with a ratio of 1:15.
| Last Split Date | Mar 22, 2024 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -12.54 |
| Piotroski F-Score | 2 |